1. Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. Issue 3 (10th January 2018) Authors: Ye, Naidong; Monk, Scott A.; Daga, Pankaj; Bender, David M.; Rosen, Laura B.; Mullen, Jamie; Minkwitz, Margaret C.; Kugler, Alan R. Journal: Clinical pharmacology in drug development Issue: Volume 7:Issue 3(2018) Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients. (4th October 2013) Authors: Sun, Hong; MacLeod, Catherine; Mostoller, Kate; Mahon, Chantal; Han, Lingling; Renger, John J.; Ma, Junshui; Brown, Kevin R.; Schulz, Valerie; Kay, Gary G.; Herring, W. Joseph; Lines, Christopher; Rosen, Laura B.; Murphy, M. Gail; Wagner, John A. Journal: Journal of clinical pharmacology Issue: Volume 53:Number 12(2013:Dec.) Page Start: 1294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗